The 6MWTd was not different between test 1 (without facemask) and test 2 (with facemasks) (405☑08 m vs 400☑03 m, P=.81). Between test 1 and test 2, the patients were stable with no change in PAH disease severity as evidenced by no change in NYHA functional class, REVEAL Lite 2.0 score, BNP concentration, right ventricular systolic pressure, right ventricular function, and pulmonary gas exchange responses to the submaximal CPET ( Table 2). Test 1 and test 2 were performed consecutively and were separated by 81±51 days.
Patient demographics are shown in Table 1 clinical data and submaximal CPET data are shown in Table 2. Abbreviations and Acronyms: 6MWT ( 6-minute walk test), 6MWTd ( 6-minute walk test distance), BNP ( brain-type natriuretic peptide), CPET ( cardiopulmonary exercise test), NYHA ( New York Hear Association), PAH ( pulmonary arterial hypertension), RPE ( rating of perceived exertion), SpO2 ( arterial oxygen saturation) This study reinforces the evidence that wearing a facemask is safe in PAH patients, even during exercise. Our findings show that wearing a facemask has no discernable impact on the arterial oxygen saturation and perceptual responses to exercise or exercise capacity in patients with moderate-to-severe PAH. Similarly, both end-test RPE and lowest SpO 2 during the 6MWT were not different in test 1 and test 2 (RPE: 2.5☑.7 vs 2.5☒.1, P=.91 SpO 2 nadir: 92.8☓.4% vs 93.3☓.3%, P=.55). Six-minute walk test distance was not different between test 1 and test 2 (405☑08 m vs 400☑03 m, P=.81). The two 6MWTs were performed 81±51 days apart, and all patients were clinically stable at both testing timepoints. At both time points, all patients also underwent a submaximal cardiopulmonary exercise test, echocardiogram, and blood laboratory tests, with a Registry to Evaluate Early and Long-Term PAH Disease Management Lite 2.0 score calculated. Each included patient performed a 6MWT without (test 1) and with (test 2) a facemask between October 1, 2019, and October 31, 2020.
Forty-five patients being treated for group 1 PAH and who performed a 6MWT before and after implementation of a facemask mandate were included in the analysis.
We performed a single-center retrospective study to evaluate whether facemask wearing impacted distanced covered, rating of perceived exertion (RPE), and arterial oxygen saturation (SpO 2) during a 6-minute walk test (6MWT) in PAH patients. Little is known about the effect of wearing a facemask on the physiological and perceptual responses to exercise in patients with pulmonary arterial hypertension (PAH).
0 kommentar(er)
